CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection

Scandinavian Journal of Gastroenterology

Volumn 33, Issue 10, 1998, Pages 1034-1038

  Sagar, M ^a   Seensalu, R ^a   Tybring, G ^a   Dahl, M L ^a   Bertilsson, L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2C19; Genotype; Helicobacter pylori; Omeprazole; Phenotype

Indexed keywords

CYTOCHROME P450; ISOENZYME; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CAUCASIAN; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GASTROINTESTINAL DISEASE; GENOTYPE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SEROLOGY;

ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUTATION; OMEPRAZOLE; PEPTIC ULCER; PHENOTYPE; POLYMERASE CHAIN REACTION;

EID: 0031762698     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655298750026714     Document Type: Article

References (26)

1. Regårdh CG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 1986;21 Suppl 118:99-104.
2. Cederberg C, Andersson T, Skånberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989; 24 Suppl 166:33-40.
3. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12:415-6.
4. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:32-7.
5. Sohn DR, Kobayashi K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from Oriental population. J Pharmacol Exp Ther 1992;262:1195-202.
6. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol Ther 1985;38:402-8.
7. Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51:388-97.
8. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. p. 657-85.
9. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese population? Clin Pharmacol Ther 1993;53:608-10.
10. Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991;31:689-92.
11. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic detect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
12. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
13. Chang M, Dahl ML, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-63.
14. Chang M, Tybring G, Dahl ML, Götharson E, Sagar M, Seensalu R, et al. Inter phenotype differences in disposition and effect on gastrin levels of omeprazole. Suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-8.
15. Roh H-K, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in Korean population. Pharmacogenetics 1996;6:547-51.
16. Labenz J, Tillenburg B, Peitz U, Idström J-P, Verdú EF, Stolte M, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in the patients with duodenal ulcer. Gastroenterology 1996;110:725-32.
17. Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984;309:347-56.
18. Tybring G, Böttiger Y, Widén J, Bertilsson L. Enantioselective hydroxylation of omeprazole catalysed by CYP2C19 in Swedish Caucasian subjects. Clin Pharmacol Ther 1997;62:129-37.
19. Befrits R, Granström M, Rylander M, Rubio C. Helicobacter pylori in 205 consecutive endoscopy patients. Scand J Infect Dis 1993;25:185-91.
20. Granström M, Tindberg Y, Blennow M. Seroepidemiology of Holicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age. J Clin Microbiol 1997;35: 468-70.
21. Dahl-Puustinen ML, Alm C, Bertilsson L, Christenson I, Östman J, Thunberg E, et al. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes. Br J Pharmacol 1990;30:476-80.
22. Rost KL, Brockmoller J, Esdorn F, Roots I. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 1995;23:268-77.
23. Verdú EF, Armstrong D, Idström J-P, Labenz J, Stolte M, Börsch G, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gasteroenterol 1996;31:1151-6.
24. Masini E, Bechi P, Dei R, Di Bello MG, Bani Sacchi T. Helicobacter pylori potentiates histamine release from rat serosal mast cells induced by bile acids. Dig Dis Sci 1994; 39:1493-500.
25. Calam J, Goldner EH, Walsh JH, Soll AH. Mononuclear cells, but not H. pylori, release gastrin from cultured G-cells via diffusable factors [abstract]. Gut 1993;34:S3-W11.
26. Helander HF, Fryklund, Walmark B. Structure and function of isolated gastric glands [abstract]. Gastroenterology 1987;92: A1431.